IPO Insider

2016's Top IPOs

  1. BeiGene, Ltd. (BGNE) 12.00%
  2. Editas Medicine (EDIT) -18.19%

Highlighted IPO

On July 1, 2015, the IPO Teladoc, Inc. (NYSE: TDOC) opened for trading at $29.90 after pricing 8,250,000 shares of its common stock at a price to the public of $19.00 per share, above the recently expected range of $15 to $17 per share.

J.P. Morgan Securities LLC and Deutsche Bank Securities Inc. are acting as joint book-running managers for the offering. William Blair & Company, L.L.C., Wells Fargo Securities, LLC and SunTrust Robinson Humphrey, Inc. are acting as co-managers for the offering.

Teladoc is the nation's first and largest telehealth platform, delivering on-demand healthcare anytime, anywhere, via mobile devices, the internet, video and phone.

Recently Priced IPOs

Date Company Ticker Shares IPO Price Current % Underwriters
2/3/2016 BeiGene, Ltd. BGNE 6.6 Mil $24.00 $26.88 12.00% Goldman, Sachs & Co., Morgan Stanley and Cowen
2/3/2016 Editas Medicine EDIT 5.9 Mil $16.00 $13.09 -18.19% Morgan Stanley, JP Morgan, Cowen and JMP Securities.
12/18/2015 Yirendai Ltd. YRD 7.5 Mil $10.00 $9.45 -5.50% Morgan Stanley, Credit Susse, China Renaissance, Needham & Company
12/10/2015 Atlassian Corporation Plc TEAM 22 Mil $21.00 $30.08 43.24% Goldman, Sachs & Co. and Morgan Stanley & Co. LLC
11/20/2015 Duluth Holdings Inc. DLTH 6.667 Mil $12.00 $14.59 21.58% William Blair, Baird, Raymond James, BMO Capital Markets
11/19/2015 Mimecast Limited MIME 7.75 Mil $10.00 $9.60 -4.00% Goldman, Sachs & Co.
11/19/2015 Axsome Therapeutics AXSM 5.667 Mil $9.00 $9.27 3.00% Ladenburg Thalmann, Cantor Fitzgerald & Co., Brean Capital
11/19/2015 Match Group MTCH 33.333 Mil $12.00 $13.55 12.92% J.P. Morgan, Allen & Company LLC, BofA Merrill Lynch
11/19/2015 Square SQ N/A $9.00 $13.09 45.44% Goldman, Sachs & Co., Morgan Stanley, JP Morgan
11/13/2015 Mesoblast Limited MESO 7.48 Mil $8.00 $6.36 -20.50% J.P. Morgan and Credit Suisse

Upcoming IPOs

Date Company Ticker Shares Expected Price Underwriters
N/AKlox Technologies, Inc.KLOXN/AN/AUBS Investment Bank, Canaccord Genuity, Needham & Company, National Bank of Canada Financial Inc.
N/AAntero Resources Corp.ARN/AN/ABarclays, Citigroup, J.P. Morgan, Credit Suisse, Jefferies, Wells Fargo Securities
N/AViking TherapeuticsVKTX5 MilN/AOppenheimer & Co. and Roth Capital
N/AViewRayVRAY4 Mil$12-$14Cowen and Company, Stifel
N/ASidoti & Company, Inc.SDTIN/AN/AWR Hambrecht + Co., Sidoti & Company
N/ANexvetNVETN/AN/ABofA Merrill Lynch and Cowen & Company
N/AHailiang Education GroupHLGN/AN/ANetwork 1 Financial Securities
N/APar Pharmaceutical Holdings, Inc.PRXN/AN/AJ.P. Morgan, Goldman, Sachs & Co., Citigroup, Morgan Stanley, BofA Merrill Lynch, Deutsche Bank Securities, Evercore ISI, RBC Capital Markets, TPG Capital BD, LLC
N/AHTG Molecular DiagnosticsHTGMN/AN/ALeerink Partners
N/ACommercial Credit, Inc.CCRN/AN/AKeefe, Bruyette & Woods, JPMorgan

Upcoming IPO

Blue Buffalo Pet Products (NASDAQ: BUFF) filed $500M IPO with the SEC. The company plans to list under symbol "BUFF" on the NASDAQ.

The offering is being led by JPMorgan and Citigroup, with Barlcys, Deutsche Bank, Morgan Stanley, Wells Fargo and LOYAL3 Securities also listed in support.

Blue Buffalo Pet Products is the fastest growing major pet food company in the United States, selling dog and cat food made with whole meats, fruits and vegetables, and other high-quality, natural ingredients. BLUE is a billion dollar brand based on sales at retail and is the #1 brand in the Wholesome Natural market segment. They currently have approximately 6% share of the overall pet food industry and feed only 2-3% of the 164 million pets in the United States.